SBC COVID-19 Update
Published on 7 Jul 2020
Freeline Closes $120 Million Series C Financing Round
Published on 2 Jul 2020
Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer
Published on 24 Jun 2020
Achilles Therapeutics to set up manufacturing operations at the CGT Catapult manufacturing centre
Published on 8 Jun 2020
Cytiva and Entos Pharmaceuticals work together to accelerate development of COVID19 vaccines
Published on 4 Jun 2020
LifeArc backs 15 patient studies into ‘re-purposed’ therapies to fight coronavirus
Published on 29 May 2020
Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens
Published on 29 May 2020
Cytiva launches VIA Capsule for the cryogenic shipment of cellular therapies
Published on 29 May 2020
Achilles Therapeutics announces formation of Scientific Advisory Board
Published on 15 May 2020

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Read the article
The appointment of these three experienced industry executives will bring valuable insight and resource to our Board and executive team. With their skills in immunology, clinical therapeutic development and strategy we have the expertise to advance our clinical programmes and look forward to the next stage of our progress.
Prof. Clive Page
Chairman of Immune Regulation
CiRA Foundation and the Cell and Gene Therapy Catapult set to launch new stem cell collaborative research
Published on 12 May 2020
Freeline receives Orphan Drug Designation from the FDA for FLT190 for the treatment of Fabry Disease
Published on 5 May 2020
Autifony Therapeutics announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders
Published on 4 May 2020
MicrofluidX raises £1.4m in seed funding to develop novel cell therapy bioprocessing technology Primary tabs
Published on 23 Apr 2020
Stevenage Bioscience Catalyst announces Hugo Villanueva as Innovation and Business Development Director
Published on 20 Apr 2020
Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia
Published on 17 Apr 2020
Ossianix is responding to the COVID-19 pandemic by developing therapeutic single domain VNAR antibodies to the COVID-19 spike protein
Published on 8 Apr 2020
Operations continue at the Cell and Gene Therapy Catapult
Published on 1 Apr 2020
LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines
Published on 2 Mar 2020
Plasticell obtains further funding to wrap up pre-clinical development of expanded cord blood stem cell product.
Published on 25 Feb 2020
Stevenage Bioscience Catalyst Life Science Opportunity Zone
Published on 20 Feb 2020
Freeline presents data on its AAV-based gene therapies for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium™
Published on 12 Feb 2020

Copyright © 2020 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.